A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

Summary

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Eligibility

Age range

18+ years

Sex

All

Healthy volunteers

No

Interventions

• Biological
  empasiprubart

  Intravenous infusion of empasiprubart

• Biological
  IVIg

  Intravenous infusion of IVIg

• Other
  empasiprubart-placebo

  A placebo resembling the empasiprubart treatment

• Other
  IVIg-placebo

  A placebo resembling the IVIg treatment

Locations (73)